

Journal of Hepatology

CTAT methods

Tables for a “Complete, Transparent, Accurate and Timely account” (CTAT) are now mandatory for all revised submissions. The aim is to enhance the reproducibility of methods.

- Only include the parts relevant to your study
- Refer to the CTAT in the main text as ‘Supplementary CTAT Table’
- Do not add subheadings
- Add as many rows as needed to include all information
- Only include one item per row

If the CTAT form is not relevant to your study, please outline the reasons why:

--

1.1 Antibodies

Name	Citation	Supplier	Cat no.	Clone no.
α-SMA		Abcam	ab5694	
TROMA-III (CK-19)		Hybridoma Bank, Iowa University		
Ki-67		Abcam	ab16667	
αvβ6		Biogen (Gift from Dr. Violette)	Ch2A1	
F4/80		Bio-Rad	MCA497R	Cl:A3-1
hABCB4		Sigma/Atlas	HPA053288	
ZO-1		Invitrogen	339100	ZO1-1A12
CD11b		R&D	MAB1124-100	M1/70
ABCB4 (human)		Thermo Scientific	MA1-35605	P3II-26
ABCB4 (mouse)		Santa Cruz	Sc-1517	
ABCB4 (human and mouse)		Thermo Scientific	MA1-26528	C219
Na ⁺ /K ⁺ -ATPase		Abcam	Ab7671	
ABCB4 (human)		LS-Bio	LS-C357461	aa601-720

1.2 Cell lines

Name	Citation	Supplier	Cat no.	Passage no.	Authentication test method
HEK293	PubMed: 11967234	ATCC (Manassas, VA)	CRL-1573™	7-10	STR

1.3 Organisms

Name	Citation	Supplier	Strain	Sex	Age	Overall n number
BALB/c. <i>Abcb4</i> ^{-/-}	Ikenaga et al. AJP 2015	Own colony of Popov lab	BALB/cAnNCrl	Male	4-6weeks	165

	PMID: 25478810					
BALB/c. <i>Abcb4</i> ^{-/-}	Ikenaga et al. AJP 2015 PMID: 25478810	Own colony of Popov lab	BALB/cAnNCrl	Female	4- 6weeks	32
BALB/c		Charles River Laboratories (Wilmington, MA)	BALB/cAnNCrl	Male	4- 6weeks	13
BALB/c		Charles River Laboratories (Wilmington, MA)	BALB/cAnNCrl	Female	4- 6weeks	9

1.4 Sequence based reagents

Name	Sequence	Supplier
		All synthesized at Biofins
Target description (gene)	Primer	Sequence
B2MG (B2m)	Forward	5'-CTG ATA CAT ACG CCT GCA GAG TTA A-3'
	Probe	5'-GAC CGT CTA CTG GGA TCG AGA CAT GTG-3'
	Reverse	5'-ATG AAT CTT CAG AGC ATC ATG AT-3'
COLIA1	Forward	5'-TCC GGC TCC TGC TCC TCT TA-3'
	Probe	5'-TTC TTG GCC ATG CGT CAG GAG GG-3'
	Reverse	5'-GTA TGC AGC TGA CTT CAG GGA TGT-3'
TIMP-1	Forward	5'-TCC TCT TGT TGC TAT CAC TGA TTA GCT T-3'
	Probe	5'-TTC TGC AAC TCG GAC CTG GTC ATA AGG-3'
	Reverse	5'-CGC TGG TAT AAG GTG GTC TCG TT-3'
TGFβ1	Forward	5'-AGA GGT CAC CCG CGT GCT AA-3'
	Probe	5'-ACC GCA ACA ACG CCA TCT ATG AGA AAA CCA-3'
	Reverse	5'-TCC CGA ATG TCT GAC GTA TTG A-3'
Igtb6	Forward	5'-GCA GAA CGC TCT AAG GCC AA-3'
	Probe	5'-TGG CAA ACG GGA ACC AAT CCT CTG T-3'
	Reverse	5'-AAA GTG CTG GTG GAA CCT CG-3'
MMP2	Forward	5'-CCG AGG ACT ATG ACC GGG ATA A-3'
	Probe	5'-TCT GCC CCG AGA CCG CTA TGT CCA-3'
	Reverse	5'-CTT GTT GCC CAG GAA AGT GAA G-3'
MMP3	Forward	5'- GATGAACGATGGACAGAGGATG-3'
	Probe	5'- TGGTACCAACCTATTTCCTGGTTGCTGC-

		3'
	Reverse	5'-AGGGAGTGGCCAAGTTCATG-3'
MMP9	Forward	5'-CAG GAT AAA CTG TAT GGC TTC TGC-3'
	Probe	5'-CTA CCC GAG TGG ACG CGA CCG T-3'
	Reverse	5'-GCC GAG TTG CCC CCA-3'
MMP12	Forward	5'-GCA GTG CCC CAG AGG TCA-3'
	Probe	5'-AGA TCC TGT AAG TGA GGT ACC GCT TCA TCC A-3'
	Reverse	5'-TCA CGC TTC ATG TCC GGA G-3'

1.5 Biological samples

Description	Source	Identifier

1.6 Deposited data

Name of repository	Identifier	Link

1.7 Software

Software name	Manufacturer	Version
Graph-Pad Prism	GraphPad Software, San Diego, CA	version 8.0

1.8 Other (e.g. drugs, proteins, vectors etc.)

--	--	--

1.9 Please provide the details of the corresponding methods author for the manuscript:

Animal experiments, histological and biochemical analysis of disease phenotype, portal pressure measurements

Yury V. Popov, email: ypopov@bidmc.harvard.edu, telephone: +1(617)667-1269, fax: +1(617)667-2767, Division of Gastroenterology, Hepatology and Nutrition, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02115, USA

Design and formulation of mRNA constructs, in vitro experiments, PC analysis via mass-spectroscopy: Paolo G. V. Martini, email: Paolo.Martini@modernatx.com, telephone: +1 (617)803-0173, fax: +1(617) 583-1998, Moderna Inc, 200 Technology Square, 6th floor, Cambridge, MA 02139, USA

2.0 Please confirm for randomised controlled trials all versions of the clinical protocol are included in the submission. These will be published online as supplementary information.

Not applicable.